袁秀萍

摘要:目的  探讨高压氧联合尼莫地平治疗脑小血管病(CSVD)所致认知功能障碍的临床疗效。方法  连续性入组2016年1月~2017年12月于新疆巴州人民医院门急诊就诊符合入排标准的CSVD患者165例,将其随机分为尼莫地平组、高压氧组和综合治疗组,每组55例。收集其临床资料,完善头颅磁共振检查及神经心理学评估,所有患者均给予基础治疗(包括合并高血压、糖尿病、高血脂者予对症治疗),在此基础上,尼莫地平组给予尼莫地平治疗,高压氧组给予高压氧治疗,综合治疗组给予尼莫地平+高压氧治疗。比较三组患者治疗前后简明精神状态检查(MMSE)评分和蒙特利尔认知功能评估量表(MoCA)总分、各分项评分、各认知领域改善情况及不良反应发生情况。结果  治疗后三组患者MMSE、MoCA评分均优于治疗前,且综合治疗组优于尼莫地平组和高压氧组,差异具有统计学意义(P<0.05),但尼莫地平组与高压氧组患者相比,差异无统计学意义(P>0.05)。三组治疗后MoCA各分项得分较前均有增长,尤其在视空间执行功能、语言能力及延迟回忆方面,差异有统计学意义(P<0.05)。综合治疗组视空间执行功能、计算力、语言能力、延迟回忆分项的得分高于尼莫地平组和高压氧组,差异具有统计学意义(P<0.05)。三组均无严重不良反应发生。结论  高压氧联合尼莫地平可明显改善CSVD患者的认知功能,具有一定的协同作用,可作为CSVD所致认知功能障碍治疗的有效方案。

关键词:高压氧;尼莫地平;脑小血管病;认知功能障碍

Abstract:Objective  To investigate the clinical efficacy of hyperbaric oxygen combined with nimodipine in the treatment of cognitive impairment caused by cerebral small vessel disease (CSVD).Methods  Continuously enrolled 165 patients with CSBD who met the criteria for admission to the emergency department of Bazhou People's Hospital from January 2016 to December 2017. They were randomly divided into nimodipine group, hyperbaric oxygen group and comprehensive treatment group , 55 cases in each group. Collecting clinical data, improving the MRI and neuropsychological assessment, all patients were given basic treatment (including symptomatic treatment of hypertension,diabetes, and hyperlipidemia). On this basis, nimodipine was given to Nemo. In the treatment of pingping, hyperbaric oxygen was given to hyperbaric oxygen therapy, and in the comprehensive treatment group, nimodipine and hyperbaric oxygen were given. The course of treatment was 3 months. The (MMSE) scores and the total scores of the Montreal Cognitive Function Assessment Scale (MoCA),the scores of each sub-item, the improvement of each cognitive field, and the occurrence of adverse reactions were compared between the three groups.Results  After treatment, the MMSE and MoCA scores of the three groups were better than those before treatment, and the comprehensive treatment group was superior to the nimodipine group and the hyperbaric oxygen group,the difference was statistically significant (P<0.05), but the nimodipine group and the hyperbaric oxygen group. There was no significant difference between the patients (P>0.05).After three treatments, the scores of MoCA sub-items increased compared with the previous ones, especially in the visual function, language ability and delayed recall the difference was statistically significant(P<0.05). The scores of spatial executive function, computational power, language ability, and delayed recall were higher in the comprehensive treatment group than in the single treatment group,the difference was statistically significant (P<0.05).No serious adverse reactions occurred in the three groups.Conclusion  Hyperbaric oxygen combined with nimodipine can significantly improve the cognitive function of patients with CSBD. It has a synergistic effect and can be used as an effective treatment for cognitive dysfunction caused by CSCD.

Key words:Hyperbaric oxygen;Nimodipine;Cerebral small vessel disease;Cognitive dysfunction

随着人口老龄化进程的加速及神经影像技术的发展,脑小血管病(cerebral small vessel disease,CSVD)逐渐被广大医务工作者认识和发现,成为近期的研究热点。CSVD是指各种原因所致的颅内小动脉、微动脉、毛细血管及小静脉病变,进而引起的一系列临床、影像、病理表现综合征[1]。影像学主要表现为脑白质病变(white matter lesions,WMLs)、腔隙性脑梗死(lacunar infarctions,LIs)、脑微出血(cerebral microbleeds,CMBs)等[2]。临床表现多样,以认知功能障碍、缺血或出血性卒中、精神情感障碍、尿便及步态异常为主。流行病学调查显示CSVD占血管性认知功能障碍病因的50%[3,4],是导致血管性痴呆的主要危险因素之一[5]。因此,早期干预和治疗CSVD所致认知功能障碍至关重要。高压氧治疗可以在一定程度提高颅内动脉的氧分压,提高脑组织的氧张力,改善脑组织低灌注,减轻脑实质损害[6]。本研究探讨高压氧联合尼莫地平治疗脑小血管病所致认知功能障碍的疗效,旨在为CSVD所致认知功能障碍的早期预防和治疗提供客观依据。

1对象与方法

1.1研究对象  连续性入组2016年1月~2017年12月于新疆库尔勒市巴州人民医院门急诊就诊的以“头晕、记忆力减退”为主诉的患者。纳入标准:①年龄50~80岁;②影像学及临床症状符合CSVD诊断标准[2]:头颅MRI提示血管源性脑白质病变Fazekas评分≥2分或腔隙性脑梗死数目≥1个或微出血数目≥2个;③近3个月内未服用对认知功能产生影响的药物。排除标准:①颅内外血管检查提示大动脉狭窄>50%及闭塞者或心源性栓塞者;②非血管源性的脑白质病变(如中毒所致);③阿尔茨海默病、帕金森病等其他原因所致认知功能障碍;④严重视、听功能障碍,不能配合或拒绝检查者;⑤严重的全身系统疾病或恶性肿瘤患者,预期生存期<6个月。共入组患者165例,将其按随机数字表法分为尼莫地平组、高压氧组、综合治疗组三组,每组55例。本研究经医院伦理会批准,患者知情同意并签署知情同意书。

1.2方法  三组治疗前评估认知功能并完善头颅MRI检查,治疗前体格检查及血、尿常规、肝肾功能、心电图、脑电图、胸片等检查未见明显异常。所有患者均给予基础治疗(即合并高血压、糖尿病、高脂血症的患者予以相应的对症治疗)。尼莫地平组在此基础上给予尼莫地平(拜耳制药,国药准字H20003010)30 mg口服,3次/d,并在服药期间停用其他钙离子拮抗剂或对疗效产生影响的药物;高压氧组除基础治疗外辅以高压氧治疗:采用国产烟台宏远氧舱厂生产的全电脑控制二舱四门式18人医用空气加压舱,设置压力参数为0.2 MPa(2ATA),升压和降压时间均为20 min,稳压面罩吸氧时间为60 min,中间休息10 min后改吸舱内空气,每次高压氧治疗持续时间为110 min,1次/d,5 d/周;综合治疗组则结合基础治疗、尼莫地平及高压氧治疗,三组患者疗程均为3个月。

1.3观察及评价指标

1.3.1认知功能评估  采用简明精神状态检查(mini mental state examination,MMSE)[7]及蒙特利尔认知功能评估量表(montreal cognitive assessment,MoCA)[8]评估三组患者治疗前后总体认知功能及各认知领域的情况。所有患者均由受过专业知识培训的神经心理学医师在安静环境下独立评估。MMSE主要用于初步评估患者总体认知功能,包括定向力、记忆力、计算力、注意力、语言能力五个部分,总分30分[7];MoCA主要用于评估患者总体认知功能及各认知领域的情况,涵盖了视空间执行功能(交替连线测验、复制立方体、画钟,共5分)、命名(3分)、注意力(3分)、计算力(3分)、语言(重复句子、语言流畅性,共3分)、抽象思维(2分)、延迟回忆(5分)、定向力(时间、地点定向,共6分)八个部分,共30分,受教育年限≤12年者总分加1分,<26分定义为认知功能障碍[8]。

1.3.2不良反应  统计三组患者治疗过程中不良反应的发生情况。

1.4统计学方法  采用SPSS 20.0软件进行数据处理,连续正态分布的计量资料以(x±s)表示,三组间比较采用单因素方差分析,两两比较采用SNK-q检验;计数资料以(%)表示,组间比较采用?字2检验或Fisher 精确概率法。检验水准α=0.05,P<0.05时差异具有统计学意义。

2结果

2.1三组患者的基线特征  三组年龄、性别、受教育程度、高血压病史、糖尿病病史、高脂血症病史、冠心病病史、吸烟和饮酒史比较,差异均无统计学意义(P>0.05),具有可比性,见表1。

2.2三组患者治疗前后总体认知功能比较  治疗前,三组患者的MMSE评分及MoCA评分比较,差异无统计学意义(P>0.05),治疗后三组患者MMSE评分可增加脑损伤部位侧枝循环的建立,改善脑组织缺氧状态,修复受损脑细胞,改善脑功能,促进认知功能恢复;③高压氧可抑制线粒体损害诱发的凋亡级联反应,降低血管通透性,修复血脑屏障,从而减轻脑组织损伤[6,14]。综合治疗通过改善脑循环、修复血脑屏障、减少神经功能缺损、保护脑细胞,最终达到有效改善或逆转CSVD所致认知功能障碍的目的。

本研究采用MMSE和MoCA两种量表对CSVD患者的认知功能进行评估,并分析各认知领域得分的差异。结果显示,CSVD患者各认知领域均有所受损,以视空间执行功能、语言能力、延迟回忆、定向力损害更为显着,与既往的研究结果类似,CSVD所致认知功能损害主要以执行功能障碍及信息处理速度下降为主[15,16]。并且研究还发现治疗后,三组患者MoCA各分项得分较前均有所增长,尤其在视空间执行功能、语言能力及延迟回忆方面。除此之外,综合治疗组患者视空间执行功能、计算力、语言能力、延迟回忆分项的得分高于尼莫地平组和高压氧组,从侧面说明了高压氧联合尼莫地平治疗能更好的改善CSVD患者的认知功能,且疗效要优于尼莫地平组和高压氧组,两者可能存在协同作用,但长期的疗效还有待进一步的研究证实。

综上所述,高压氧联合尼莫地平治疗对神经功能恢复、认知功能改善疗效显着,且不良反应少,安全性可以保证,可作为脑小血管病所致认知功能障碍治疗的有效方案。但本研究样本量较小,疗程短,远期疗效还有待大规模随机对照试验证实。

参考文献:

[1]Wardlaw JM,Smith C,Dichgans M.Mechanisms of sporadic cerebral small vessel disease:insights from neuroimaging[J].Lancet Neurol,2013,12(5):483-497.

[2]Wardlaw JM,Smith EE,Biessels GJ,et al.Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration[J].Lancet Neurology,2013,12(13):822-838.

[3]Wallin A,Roman GC,Esiri M,et al.Update on vascular cognitive impairment associated with subcortical smallvessel disease[J].Journal of Alzheimer's Disease,2018,62(3):1417-1441.

[4]Teng Z,Dong Y,Zhang D,et al.Cerebral small vessel disease and post-stroke cognitive impairment[J].International Journal of Neuroscience,2017,127(9):824-830.

[5]Smith EE,Beaudin AE.New insights into cerebral small vessel disease and vascular cognitive impairment from MRI[J].Current Opinion in Neurology,2018,31(1):36-43.

[6]Wang RY,Chang HC,Chen CH,et al.Effects of hyperbaric oxygenation on oxidative stress in acute transient focal cerebral ischemic rats[J].European Journal of Applied Physiology,2012,112(1):215-221.

[7]Folstein MF,Folstein SE,Mchugh PR."Mini-mental state":A practical method for grading the cognitive state of patients for the clinician[J].Journal of Psychiatric Research,2015,12(3):189-198.

[8]Nijsse B,Visser-Meily JMA,Van Mierlo M,et al.Temporal Evolution of Poststroke Cognitive Impairment Using the Montreal Cognitive Assessment[J].Stroke,2017,48(1):98-104.

[9]脑小血管病诊治专家共识组.脑小血管病的诊治专家共识[J].中华内科杂志,2013,52(10):893-896.

[10]Kovács KR,Czuriga D,Bereczki D,et al.Silent brain infarction-a review of recent observations[J].International Journal of Stroke,2013,8(5):334-347.

[11]Wang P,Wang Y,Feng T,et al.Rationale and design of a double-blind,placebo-controlled,randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events(NICE)[J].BMC Neurology,2012,12(1):88.

[12]杨艳丽,廖群芬,林萃,等.脑小血管病不同分型伴非痴呆型血管性认知功能障碍程度比较及尼莫地平干预分析[J].疑难病杂志,2018(4):352-356.

[13]Chen CH,Chen SY,Wang V,et al.Effects of Repetitive Hyperbaric Oxygen Treatment in Patients with Acute Cerebral Infarction:A Pilot Study[J].The Scientific World Journal,2012,2012(7):1-5.

[14]Ding Z,Tong WC,Lu XX,et al.Hyperbaric Oxygen Therapy in Acute Ischemic Stroke:A Review[J].Interventional Neurology,2014,2(4):201-211.

[15]倪俊,徐运.脑小血管病转化医学研究中国专家共识[J].中国卒中杂志,2018(8):853-870.

[16]Benjamin P,Lawrence AJ,Lambert C,et al.Strategic lacunes and their relationship to cognitive impairment in cerebral small vessel disease[J].Neuroimage Clin,2014(4):828-837.

收稿日期:2019-6-8;修回日期:2019-6-18

编辑/杨倩